Promising Cancer Cure Hits the Market! [Car-T Cells]

Promising Cancer Cure Hits the Market! [Car-T Cells]

From ColdFusion by Dagogo

May 5, 2026 · 15 min

About this episode

This episode discusses the market introduction of a promising cancer treatment involving CAR-T cells.

Subscribe here: https://goo.gl/9FS8uF Become a Patron!: https://www.patreon.com/ColdFusion_TV CF Bitcoin address: 13SjyCXPB9o3iN4LitYQ2wYKeqYTShPub8 Hi, welcome to ColdFusion (formerly known as ColdfusTion). Experience the cutting edge of the world around us in a fun relaxed atmosphere. Sources: https://www.ncbi.nlm.nih.gov/pubmed/27068948 https://videocast.nih.gov/Summary.asp?file=19892&bhcp=1 http://fortune.com/2017/08/31/novartis-kymriah-car-t-cms-price/ https://pharmaphorum.com/news/scotlands-tc-biopharma-joins-bluebird-develop-next-gen-car-t/ https://www.ncbi.nlm.nih.gov/pubmed/20668228 https://www.cancer.gov/about-cancer/treatment/types/immunotherapy https://labiotech.eu/bluebird-bio-tc-biopharm-car-t-cells/ https://www.cancer.gov/about-cancer/treatment/research/car-t-cells https://www.statnews.com/2017/08/30/novartis-car-t-cancer-approved/ https://www.bloomberg.com/news/articles/2017-09-22/novartis-s-475-000-price-tag-on-cancer-drug-meets-resistance https://futurism.com/the-u-s-fda-just-approved-a-treatment-that-reprograms-cells-to-fight-cancer/ 1:50 https://www.youtube.com/watch?v=hNJdApQwCxU…

People in this episode

Host: Dagogo

Topics covered

  • cancer treatment
  • CAR-T cells
  • immunotherapy
  • biopharmaceuticals
  • healthcare innovation

Keywords

  • cancer cure
  • CAR-T therapy
  • Novartis
  • Kymriah
  • immunotherapy
  • biopharma
  • healthcare

Mentioned in this episode

Organizations: Novartis, TC Biopharma, Bluebird Bio, NIH, Fortune, Stat News, Bloomberg, Futurism

Products: Kymriah

Books & works: Cloud City, Echoes, Fading Light, Paths, First Weeks, Honour, Arc, As Close To Me As You Are Now

More episodes of ColdFusion

Explore listener stats, chart rankings, contacts and more on the ColdFusion podcast page.